RE:$1.15Management has said that they would focus on the small molecule program and then have immediately taken all 4050 indications off their trial planning milestones. To another institution looking at a potential investment, who would invest with Thomvest being the debt holder and majority equity shareholder. It certainly seems that it is going private and has been a long term plan. Thomvest knows the offers on table in 2018 for 4050. Why wouldn't they drop the value of company to zero and take the tax loss and offer it privately to big pharmas like Boehringhers of the world. Should be interesting to see how this turns out.
StockReddy wrote: Hmn